Stemedica Cell Technologies (Stemedica) has been granted a license by the State of California’s Food & Drug Branch to manufacture stem cells for human clinical trials. The Drug
Ascent Scientific has announced the availability of the first commercial source of TMCB – a new kinase inhibitor that is selective for CK2. It is more selective than
Sanofi Pasteur has reported that United Nations agency has awarded contracts to Shantha Biotechnics (Shantha) for supplies of pentavalent vaccine SHAN5 (combination vaccine of Diphtheria, Pertussis, Tetanus, Haemophilus
Integrated DNA Technologies (IDT) has been awarded $99,750 by the National Institutes of Health ARRA (American Recovery and Reinvestment Act) funding to continue work on its research project
ResearchPoint has announced the formation of a new resource management organization. The affiliate organization, ResourcingPoint, has been spun-off to provide contract clinical research associates (CRAs) to meet Sponsors’
Zealand Pharma has reported that it is developing a new treatment, ZP2929, for Type 2 Diabetes. ZP2929 has the potential to significantly decrease body weight and reduce the
Basilea Pharmaceutica ( Basilea) has reported that the FDA has accepted the complete response submitted by the Johnson & Johnson. The Complete Response submission addresses the FDA Complete
Studies conducted by Kowa showed that the patients treated with Livavo (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C)
TransPharma has reported the successful completion of the phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis. Reportedly, in June 2008, Eli
Icagen has reported top line results of a randomized, double-blind, placebo-controlled, proof-of-mechanism phase IIa study of senicapoc in allergic asthma. Senicapoc reduced the late asthmatic response (LAR) to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.